ArticleContemporary clinical trials communications2023

A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment.

JoAnn Difede et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.